Okay, so shoot me. Back long ago, in the days when Cyrus roamed the earth, CYDY definitively abandoned its efforts to combat Covid. I heard that. I even understood it -- we don't have the loot to pursue every indication, and Long Covid is a will-o-the-wisp, a Scarlet Pimpernel of a syndrome, with many indications and a strong tang of vagueness hanging about it.

Yeahbut. In February the NEH announced that it would bolster "RECOVER" Long COVID research efforts through an infusion of $515 million. I don't believe the clinical trials are yet set in stone.

We recall the 2022 findings by Drs. Yang, Recknor, and Sacha, among others,

Quote:

---

In an exploratory trial treating “long COVID” with the CCR5-binding antibody leronlimab, we observed significantly increased blood cell surface CCR5 in treated symptomatic responders but not in nonresponders or placebo-treated participants. These findings suggest an unexpected mechanism of abnormal immune downmodulation in some persons that is normalized by leronlimab.

---

Wouldn't it be reasonable to think that someone at CYDY could approach the clinical trials leaders of the RECOVER program, now that Leron is off its hold, to suggest that it be used in the NIH-sponsored trials?

Here's who should be contacted:

Quote:

---

The CT-DCC at the Duke Clinical Research Institute (DCRI) is led by Kanecia Zimmerman, MD, PhD, MPH; Christina Barkauskas, MD; and Sean O’Brien, PhD. The DCRI, in collaboration with the National Institutes of Health (NIH) and RTI, will support platform protocols designed to simultaneously test multiple possible treatments for Long COVID including drugs, cognitive interventions, devices, and other therapies.

---

Study plans are NOT finalized.

I'm aware that this message is luridly permeated with some gung-ho naivete. Apologies. One cannot help oneself.